These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 9380819)

  • 1. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer.
    Zagars GK; Pollack A
    Radiother Oncol; 1997 Sep; 44(3):213-21. PubMed ID: 9380819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The fall and rise of prostate-specific antigen. Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer.
    Zagars GK; Pollack A
    Cancer; 1993 Aug; 72(3):832-42. PubMed ID: 7687516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
    Zagars GK; Pollack A; von Eschenbach AC
    Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era.
    Zagars GK; Pollack A; von Eschenbach AC
    Cancer; 1997 Apr; 79(7):1370-80. PubMed ID: 9083160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-specific antigen. An important marker for prostate cancer treated by external beam radiation therapy.
    Zagars GK; von Eschenbach AC
    Cancer; 1993 Jul; 72(2):538-48. PubMed ID: 7686443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
    Lee AK; Levy LB; Cheung R; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling postradiation prostate specific antigen level kinetics: predictors of rising postnadir slope suggest cure in men who remain biochemically free of prostate carcinoma.
    Hanlon AL; Moore DF; Hanks GE
    Cancer; 1998 Jul; 83(1):130-4. PubMed ID: 9655302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome.
    Zagars GK; Pollack A
    Urology; 1995 Mar; 45(3):476-83. PubMed ID: 7533459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer.
    Zagars GK; Pollack A; Kavadi VS; von Eschenbach AC
    Int J Radiat Oncol Biol Phys; 1995 May; 32(2):293-306. PubMed ID: 7538498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate specific antigen regression and progression after androgen deprivation for localized and metastatic prostate cancer.
    Fowler JE; Pandey P; Seaver LE; Feliz TP; Braswell NT
    J Urol; 1995 Jun; 153(6):1860-5. PubMed ID: 7538599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer.
    Pollack A; Zagars GK; Kavadi VS
    Cancer; 1994 Jul; 74(2):670-8. PubMed ID: 7518341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy.
    Zagars GK
    J Urol; 1994 Nov; 152(5 Pt 2):1786-91. PubMed ID: 7523725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: prognostic implications.
    Kavadi VS; Zagars GK; Pollack A
    Int J Radiat Oncol Biol Phys; 1994 Sep; 30(2):279-87. PubMed ID: 7523340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. External beam radiotherapy for clinically node-negative, localized hormone-refractory prostate cancer: impact of pretreatment PSA value on radiotherapeutic outcomes.
    Akimoto T; Kitamoto Y; Saito J; Harashima K; Nakano T; Ito K; Yamamoto T; Kurokawa K; Yamanaka H; Takahashi M; Mitsuhashi N; Niibe H
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):372-9. PubMed ID: 15145150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations.
    Lee WR; Hanks GE; Hanlon A
    J Clin Oncol; 1997 Jan; 15(1):230-8. PubMed ID: 8996147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship of tumor DNA-ploidy to serum prostate-specific antigen doubling time after radiotherapy for prostate cancer.
    Pollack A; Zagars GK; el-Naggar AK; Terry NH
    Urology; 1994 Nov; 44(5):711-8. PubMed ID: 7526527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment prostate specific antigen doubling times: use in patients before radical prostatectomy.
    Goluboff ET; Heitjan DF; DeVries GM; Katz AE; Benson MC; Olsson CA
    J Urol; 1997 Nov; 158(5):1876-8; discussion 1878-9. PubMed ID: 9334621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate.
    Zagars GK; Pollack A; Smith LG
    Int J Radiat Oncol Biol Phys; 1999 Jul; 44(4):809-19. PubMed ID: 10386637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum testosterone--a significant determinant of metastatic relapse for irradiated localized prostate cancer.
    Zagars GK; Pollack A; von Eschenbach AC
    Urology; 1997 Mar; 49(3):327-34. PubMed ID: 9123693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.